Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience

Tatar B., Kose Ş., Ergun N. C., Turken M., Onlen Y., YILMAZ Y., ...More

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, vol.65, no.12, pp.1470-1475, 2019 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 65 Issue: 12
  • Publication Date: 2019
  • Doi Number: 10.1590/1806-9282.65.12.1470
  • Journal Name: REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1470-1475
  • Keywords: Hepatitis C, End-Stage Renal Disease, Sustained Virologic Response, SUSTAINED VIRAL RESPONSE, VIRUS GENOTYPES, INFECTION, INTERFERON, METAANALYSIS, EFFICACY, OMBITASVIR/PARITAPREVIR/RITONAVIR, COMBINATION, IMPAIRMENT, MANAGEMENT
  • Dokuz Eylül University Affiliated: No

Abstract

OBJECTIVE: The recent development of direct-acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C, and interferon-based regimes have become a poor treatment choice in clinical practice. Today DAAs offer shorter, well-tolerated, highly effective curative therapies. This study aimed to evaluate the effectiveness and safety of DAAs in patients with end-stage renal disease and HCV genotype 1 infection in real clinical practice.